Holmes Jonathan M, Strauber Samara, Quinn Graham E, Cole Stephen R, Felius Joost, Kulp Marjean
Department of Ophthalmology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA.
J AAPOS. 2008 Dec;12(6):581-4. doi: 10.1016/j.jaapos.2008.04.017. Epub 2008 Oct 30.
The Amblyopia Treatment Index (ATI) is a parental questionnaire that has been used to assess the impact of patching or atropine treatment on the child and family in several amblyopia treatment studies. The 18-item parental questionnaire was designed with versions for treatment with patching or atropine. We pooled data across studies to further evaluate the validity of the ATI, to further assess the presence or absence of factors (subscales).
A parent or guardian completed the ATI for 794 children who participated in 1 of 4 randomized clinical trials. Internal consistency reliability was assessed with Cronbach's alpha, and factor analysis was performed.
The ATI demonstrated high internal consistency reliability, with a Cronbach's alpha of 0.88 (95% CL = 0.87, 0.89). Factor analysis revealed the same 3 minimally overlapping factors found in the original validation study, which were again labeled "adverse effects," "treatment compliance," and "social stigma." Two of the 18 items did not load with any factor and could reasonably be omitted from future ATI administrations.
The ATI is a useful instrument for assessing the impact of patching or atropine treatment on the child and family.
弱视治疗指数（ATI）是一份家长问卷，已在多项弱视治疗研究中用于评估遮盖或阿托品治疗对儿童及其家庭的影响。这份包含18个条目的家长问卷设计了针对遮盖或阿托品治疗的不同版本。我们汇总了各项研究的数据，以进一步评估ATI的有效性，并进一步评估各因素（子量表）的存在情况。
一位家长或监护人对参与4项随机临床试验之一的794名儿童完成了ATI问卷。使用克朗巴哈系数评估内部一致性信度，并进行因子分析。
ATI显示出较高的内部一致性信度，克朗巴哈系数为0.88（95%置信区间 = 0.87, 0.89）。因子分析揭示了在最初的效度研究中发现的相同的3个最小重叠因子，它们再次被标记为“不良反应”、“治疗依从性”和“社会耻辱感”。18个条目中有2个未加载任何因子，在未来的ATI问卷施测中可以合理地省略。
ATI是评估遮盖或阿托品治疗对儿童及其家庭影响的有用工具。
